MoonLake Immunotherapeutics

US$11.53As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:MLTXHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR 1.96%
Div yield —
ROE (81.47%)
Biotechnology
Beta (5Y) 1.13
PE TTM —
TSR TTM 14.16%
Mkt cap US$981.3M
ROIC (40.69%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$15
26.88%
(74.71%)
Hold 2|8|11|5|1
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.20
0.21
0.20
0.20
5.06%
10.01%
3.89%
7.00%
Revenue$M
114.5
111.6
116.9
120.7
6.34%
(1.72%)
(0.14%)
5.32%
Peers (US$981.3M)
Cap (US$)
PE
1.343B
—
462.4M
—
Capital
TTM
5Y
10Y
Leveragex
0.588
0.327
0.265
EBIT/Intx
1.063
0.159
0.156
Own earn%
4.30
91.60
96.64
Sh yield%
6.08
39.27
39.11
Owners
Insiders/Inst%
4.45
24.35
Short interest%
3.65
SBC / revenue%
3.45
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
13
Op margin range%
8–13
$1 testx
—
Incr. ROIC%
3